Scotland Court Greenlights Talcum Powder Cancer Lawsuit Against Johnson & Johnson — What It Means for Women Who Used Baby Powder for Years
You are reading this at an hour when most people are asleep. A news story crossed your screen about women in Scotland — Aberdeen, Drongan, Glasgow — who were given permission by their country’s highest civil court to sue Johnson & Johnson over talcum powder they used for decades. And the question that brought you here is the one no one should have to type into a search engine at 2 a.m.: could what happened to me — or to my mother, my wife, my sister — be connected to a product I trusted every single day?
We are Attorney911 — The Manginello Law Firm, PLLC. We are a trial firm that handles toxic tort and product liability cases, and we built this page for one person: the woman, or the family of a woman, who used Johnson & Johnson baby powder for years and was later diagnosed with ovarian cancer or mesothelioma, and who is now sitting at a kitchen table trying to understand whether a household product she trusted from childhood could have caused the disease that is rewriting her life. The Scottish ruling is the news hook — but the evidence, the corporate conduct, and the legal rights at the center of that case are the same ones at issue in courts across the United States. This page explains what that evidence is, who may have a claim, what the law allows, what the company will argue, what proof must be preserved before it disappears, and what a case like this is honestly worth. Everything here is legal information, not legal advice. The consultation is free. The call is 1-888-ATTY-911. We answer 24 hours a day, and we don’t get paid unless we win your case.
What the Court of Session Decided — and Why It Matters Beyond Scotland
The Court of Session in Edinburgh is Scotland’s supreme civil court. In this ruling, the court granted permission for group proceedings — the Scottish equivalent of a class or mass action — to go forward against Johnson & Johnson and its former consumer-health spinoff, Kenvue. The decision came at the permission stage, which is the point where the court decides two things: whether the claims have a real chance of succeeding, and whether a group action is an appropriate way to bring them. The court found that both thresholds were met.
That matters. It is the first contaminated-talc group action ever raised in the Scottish courts. But it is not the first of its kind anywhere. Thousands of similar claims are already pending in England and Wales. In the United States, the Johnson & Johnson talc mass tort is one of the largest and most consequential product-liability campaigns in American legal history — with cases filed in state and federal courts across the country, including consolidated proceedings in federal court. The Scottish ruling is significant because it shows that courts in multiple jurisdictions are looking at the same evidence — a 1960s internal corporate memo, decades of marketing a product as “pure” and “safe for babies,” and women who used that product daily and then developed cancer — and concluding that these claims deserve their day in court.
The women in the Scottish action allege that Johnson & Johnson sold talcum powder contaminated with asbestos — specifically tremolite, a form of asbestos — and that the company knew about the danger for decades and suppressed the information. They or their loved ones developed ovarian cancer after prolonged use. One of the claimants, a 67-year-old woman from Aberdeen, was diagnosed with stage four ovarian cancer in 2024 after using the company’s talcum powder for decades. She tested negative for genetic cancer markers — meaning the hereditary factors that often explain ovarian cancer were ruled out, which sharpens the question of what else could have caused it. Another claimant, a former Glasgow city council manager, had to leave her job after her diagnosis. A third, from Drongan, was diagnosed in July 2024.
These are not abstractions. These are women who used a product they trusted from childhood, who did everything right, and who are now fighting for their lives. If that description fits you or someone you love, the legal rights described on this page may apply — not in Scotland, but in a United States courtroom, under the laws of your state.
The 1960s Memo — the Corporate Knowledge That Changes Everything
The single most powerful piece of evidence in the talc litigation is a memo from the 1960s. According to the claimants, Johnson & Johnson sought advice from scientists regarding the safety of tremolite — a type of asbestos — within its talc products. The memo’s advice was stark:
The memo advised that the use of tremolite should be minimised and that the safety of talc for babies could no longer be guaranteed.
Read that sentence again. In the 1960s — more than half a century ago — the company’s own scientific advisors told it that the asbestos in its talc was dangerous enough that it should be minimized, and that the product’s safety for babies, the very population it was marketed to, could no longer be assured. The claimants allege that Johnson & Johnson continued to market the powder as pure, gentle, and safe for babies for decades after that memo was written — without warning consumers about asbestos contamination or cancer risk.
This is the evidence that transforms a talc case from a difficult causation question into a corporate-accountability fight. When a company has internal knowledge of a danger and chooses not to warn the people using its product, that is not a design-defect question alone — it is a failure-to-warn claim, a fraudulent-concealment claim, and in jurisdictions that permit them, a punitive-damages claim. The 1960s memo is the foundation of all three.
In the United States, much of the corporate-document record from the talc litigation has already been produced through discovery in prior cases — internal testing memos, safety evaluations, marketing decisions, and communications that contradicted the company’s public safety assurances. Additional documents may exist, but the Kenvue corporate separation in August 2023 may affect document custody and availability, making early preservation demands critical.
Who May Have a Talcum Powder Cancer Claim
Not every woman who used talcum powder and developed ovarian cancer has a legal claim, and we will never tell you otherwise. But if the following facts describe your situation, a confidential case evaluation can determine whether the connection is strong enough to pursue.
You may have a claim if:
- You used Johnson & Johnson talcum powder or baby powder regularly — daily or near-daily — for years or decades, particularly for personal hygiene in the genital area
- You were diagnosed with ovarian cancer, and especially if you tested negative for genetic markers such as BRCA mutations that would otherwise explain the cancer
- You were diagnosed with mesothelioma and have a history of prolonged talcum powder use, particularly if you have no known occupational asbestos exposure
- You lost a loved one to ovarian cancer or mesothelioma and she had a decades-long history of talcum powder use
The genetic-marker-negative factor is especially significant. When a woman tests negative for BRCA and other hereditary cancer markers, the usual genetic explanation for ovarian cancer is eliminated — which strengthens the argument that an external exposure, like asbestos-contaminated talc, caused the disease. One of the Scottish claimants described this exact pattern: she was diagnosed with stage four ovarian cancer at 67, had used the powder for decades, and tested negative for genetic markers. “I don’t have any other reason for having this disease,” she said. That is the kind of fact pattern that turns a general possibility into a specific causation argument.
You should know what the defense will argue. Johnson & Johnson and Kenvue have consistently maintained that their talc products are safe and do not contain asbestos. A Kenvue spokesperson said in a public statement: “Robust science — backed by years of testing by independent and leading laboratories, universities, and health authorities around the world — shows that JOHNSON’S® Baby Powder has always been safe.” The defense in ovarian-cancer cases will challenge causation aggressively — citing epidemiological studies, arguing the absence of a universally accepted biological mechanism for how talc exposure in the genital area causes ovarian cancer, and pointing to alternative risk factors. In mesothelioma cases, the causal link to asbestos is more directly established, but the defense will argue the exposure came from other sources.
We tell you this not to discourage you, but because honesty is what a person in your position deserves. A strong case is built by knowing what the other side will argue and preparing the evidence to answer it — not by pretending the fight will be easy.
The Science: Why Talc and Asbestos Are Found Together
Talc is a mineral. It is mined from the earth. And the geology of how talc deposits form is the scientific foundation of every talc-asbestos case.
Talc and asbestos are frequently found together in the same geological deposits. They form under similar conditions — both are magnesium silicate minerals — and when talc is mined, asbestos fibers, including tremolite and anthophyllite, can be present in the ore. The question is not whether asbestos can be in talc — geology answers that. The question is whether the mining, processing, and testing protocols used by a specific manufacturer were sufficient to remove or detect the asbestos before the product reached a consumer.
The claimants in the Scottish action cite the 1960s memo about tremolite specifically. Tremolite is one of the six recognized types of asbestos. It is a known human carcinogen — regulated by the EPA under multiple statutes, including the Toxic Substances Control Act, and by OSHA in workplace settings. Asbestos exposure is the primary cause of mesothelioma, a cancer of the lining of the lungs or abdomen that is so specifically associated with asbestos that the disease itself is near-conclusive proof of exposure. The link between asbestos and ovarian cancer has been recognized by the International Agency for Research on Cancer, which classifies asbestos as a Group 1 known human carcinogen.
The defense will argue that cosmetic-grade talc is purified and does not contain detectable asbestos. Plaintiffs counter with testing — including independent laboratory analysis of retained product containers — that has found asbestos fibers in talcum powder samples. The method of testing matters: transmission electron microscopy is the analytical method capable of detecting the finest asbestos fibers, and not all testing protocols used historically by the industry were sensitive enough to find them.
This is why physical evidence — the actual product containers a woman kept in her bathroom cabinet for decades — can be decisive. A retained bottle of Johnson & Johnson baby powder can be independently tested for asbestos contamination. But those containers are increasingly rare. Talc-based baby powder was discontinued in the UK in 2023 and has been phased out in US markets. Every day that passes, more physical evidence is discarded, used up, or thrown away.
The Medicine: Ovarian Cancer and Mesothelioma After Talc Exposure
We are going to talk about the disease the way a treating oncologist would — because understanding the medicine is understanding the case.
Ovarian cancer is often called a “silent killer” because its symptoms — bloating, pelvic pain, urinary urgency, feeling full quickly — are vague and easily attributed to other causes, which means it is frequently diagnosed at an advanced stage. Stage four ovarian cancer, like the diagnosis the Aberdeen claimant received, means the cancer has spread beyond the ovaries to distant organs. Treatment typically involves surgical debulking — removing as much tumor as possible — followed by chemotherapy, and in some cases targeted therapy or immunotherapy. The five-year survival rate for stage four ovarian cancer is low. The medical costs are enormous: surgical intervention, chemotherapy regimens, ongoing oncological monitoring, and in advanced cases, palliative care.
The proof problem in an ovarian-cancer talc case is specific causation — proving that this woman’s cancer was caused by this product, not by genetics, endometriosis, obesity, hormone therapy, or simply bad luck. This is where the genetic-marker-negative factor becomes powerful. When BRCA testing and other hereditary markers come back negative, the most common alternative explanation is eliminated. Combined with a documented decades-long exposure history, the specific-causation argument becomes substantially stronger.
The defense will challenge this. They will cite epidemiological studies — some of which show an elevated risk of ovarian cancer with genital talc use, and some of which do not — and argue that the science is unsettled. They will retain their own experts to testify that the biological mechanism is unproven. In US courts, expert testimony must survive the Daubert or Frye admissibility standard, depending on the jurisdiction, which means the plaintiff’s causation experts must demonstrate that their opinions are based on reliable methodology. This is a threshold battle that can determine whether a case ever reaches a jury.
Mesothelioma is a different story. Mesothelioma is a cancer of the mesothelium — the thin lining that covers the lungs, abdomen, and other internal organs. It is so specifically associated with asbestos exposure that a mesothelioma diagnosis is itself near-conclusive proof that the patient was exposed to asbestos at some point. The latency period — the time between exposure and diagnosis — is typically 20 to 50 years. A woman who used talcum powder daily in her twenties may not develop mesothelioma until her sixties or seventies. The disease is almost always fatal, with median survival measured in months to a few years. Treatment may include surgery, chemotherapy, radiation, and immunotherapy, but the prognosis is poor.
The article references a $1.5 billion verdict awarded in Baltimore to a woman who developed mesothelioma after a lifetime of using J&J talc products. That figure represents the extreme high end of the verdict spectrum, and we must be clear: a verdict is a jury’s decision, not a final recovery. Verdicts are frequently reduced on appeal, and the procedural status of any specific verdict must be confirmed before it is cited as a settled result. What the Baltimore verdict does demonstrate is that juries, when presented with the evidence, have been willing to assign extraordinary value to the harm caused by asbestos-contaminated talc.
If you or a loved one has been diagnosed with either cancer and has a history of long-term talcum powder use, the medical records — pathology reports, genetic testing results, treatment history, and imaging — are the foundation of the case. Those records should be collected immediately. Treating facilities have varying retention policies, and records can be archived, purged, or become difficult to obtain over time.
The Defendant Structure: Johnson & Johnson, Kenvue, and the Corporate Shell Game
Johnson & Johnson is one of the largest pharmaceutical and consumer-products companies in the world. Understanding who is actually liable — and who actually has the money to pay — requires understanding the corporate structure.
Johnson & Johnson (parent corporation) manufactured and marketed talcum powder products for decades. The 1960s memo referenced in the Scottish action was a J&J internal document. The marketing campaigns that sold the powder as “pure” and “safe for babies” were J&J campaigns. For the decades during which most claimants were exposed, Johnson & Johnson was the defendant.
Kenvue is the former J&J consumer-health business that was separated as an independent company in August 2023. Kenvue now owns brands like Band-Aid, Tylenol, and Listerine — and it is named as a defendant in the Scottish lawsuit. According to public statements reported in the article, Johnson & Johnson has stated that Kenvue indemnified J&J for all talc-related litigation outside the United States and Canada. That means in the Scottish case, Kenvue may be the primary defendant. But in US cases, both entities may face liability depending on the corporate-separation structure and the indemnification agreements — which are a critical discovery target.
Talc supply-chain entities — the companies involved in mining, processing, and supplying cosmetic-grade talc to J&J — are potential additional defendants or third-party targets in US cases. The talc supply chain and its asbestos-contamination controls have been a focus of US talc litigation, and identifying who mined, processed, and shipped the talc that went into a specific product can open additional paths to accountability.
Johnson & Johnson also attempted a novel corporate-restructuring defense strategy widely known as the “Texas Two-Step” — transferring talc liabilities to a subsidiary and seeking bankruptcy protection to manage its aggregate exposure. Courts rejected that strategy, leaving the company to face ongoing litigation in civil courts. The fact that a company of this size attempted to use bankruptcy to wall off cancer claims — and failed — tells you something about the scale of the liability it faces.
For a reader, what this means practically is that the company on the label may not be the only entity with responsibility, and the entity that holds the insurance or the assets may not be the one whose name you recognize. Identifying every defendant in the chain — the manufacturer, the marketer, the supplier, the corporate parent, the spinoff — is part of the work.
The Regulatory Gap: Why the FDA Did Not Stop This
In the United States, the Food and Drug Administration regulates cosmetics under the Federal Food, Drug, and Cosmetic Act. But here is the regulatory gap that plaintiffs argue Johnson & Johnson exploited: the FDA does not require pre-market approval for cosmetic products, including talc-based powders.
Unlike drugs, which must be proven safe and effective before they reach consumers, cosmetics enter the market without federal safety review. The FDA’s authority over cosmetics is largely reactive — it can act after problems emerge, but it does not gate-keep the front door. This means that a talcum powder containing asbestos could legally be sold to millions of consumers without any federal agency having reviewed the product for carcinogenic contamination before it reached store shelves.
The FDA has conducted surveys and testing of talc-containing cosmetics for asbestos contamination and has issued guidance on testing methodologies. Asbestos itself is a known human carcinogen regulated by the EPA under multiple statutes, including the Toxic Substances Control Act. OSHA regulates asbestos in workplace air. But the disconnect between weak cosmetic-talc oversight and the well-established hazards of asbestos exposure has been a central regulatory theme in the US talc litigation — and it is part of the story of how a product containing a known carcinogen could remain on bathroom shelves for decades.
The sale of baby powder containing talc was stopped in the UK in 2023. In the US, Johnson & Johnson has also been phasing out talc-based powder. But for the women who used it for decades before those decisions, the exposure already happened. The regulatory gap is not a defense for the company — if anything, it is an explanation for how the danger persisted, and it underscores why the civil justice system, not the regulatory system, has been the primary mechanism for accountability.
Evidence Preservation: What Exists, Who Holds It, and How Fast It Disappears
Every talc cancer case lives or dies on evidence. Some of that evidence is corporate — produced in prior litigation, held in company files. Some of it is medical — your diagnosis, your pathology, your genetic testing. And some of it is physical — the actual product you used, sitting in a bathroom cabinet or a closet, possibly for decades. Each category of evidence has a different clock, and each clock is ticking.
Internal J&J corporate documents — including the 1960s tremolite memo and subsequent internal communications about asbestos testing, safety evaluations, and marketing decisions — prove knowledge of the contamination risk and support fraudulent-concealment and punitive-damages claims. Much of this documentary record has been produced in prior US litigation, but additional documents may exist. The Kenvue corporate separation may affect document custody and availability. These documents are held by the defendants and are obtained through discovery — but the preservation demand that freezes them goes out the day you call a lawyer.
Claimant medical records — including pathology reports, genetic-testing results, and complete treatment history — establish the diagnosis, the cancer type and staging, the absence of genetic markers (which supports product causation over hereditary factors), and quantify medical damages. These should be collected immediately. Treating-facility retention policies vary, and records may be archived or purged over time. The genetic-testing results are especially critical: a negative BRCA panel eliminates the most common alternative explanation and sharpens the causation argument.
Product containers, labels, and purchase receipts — these establish product identification, duration and pattern of use, and the specific product formulation used. Containers may also retain talc samples that can be independently tested for asbestos contamination. But here is the urgency: consumers may have discarded products after use, and talc-based baby powder has been discontinued in the UK since 2023 and phased out in US markets. Remaining containers are increasingly scarce as physical evidence. If you still have a bottle of Johnson & Johnson talcum powder — any bottle, any size, any vintage — do not discard it. Store it in a sealed container. It may be testable.
Independent laboratory testing of retained talc product samples can provide direct physical evidence of asbestos contamination in the specific product used. Testing should be conducted promptly by accredited laboratories using validated analytical methods such as transmission electron microscopy — the method capable of detecting the finest asbestos fibers. Product samples degrade or are discarded over time, and the defense will challenge any testing that is not conducted to exacting standards.
The preservation letter — the formal demand that tells the company and every related entity to freeze every relevant document, every sample, every internal communication — is the first thing a trial firm sends. Not after the case is filed. Not after the medical records are collected. The day you call. Because the evidence that proves what the company knew and when it knew it is the evidence that can legally disappear if no one demands it be saved.
The Defense Playbook: What Johnson & Johnson Will Argue — and How Each Play Is Answered
Johnson & Johnson is represented by some of the most sophisticated defense lawyers in the world. They have a playbook, and it has been refined across thousands of cases. Here are the moves you should expect — and the counter to each.
Play 1: “Our talc does not contain asbestos.” The company has maintained for decades that its cosmetic-grade talc is purified and free of asbestos fibers. The counter is testing — independent laboratory analysis of retained product containers using transmission electron microscopy has found asbestos in talcum powder samples. The 1960s memo about tremolite undermines the claim that the company was unaware of contamination. And the geological reality — talc and asbestos form in the same deposits — means the question is not whether contamination is possible but whether the company’s testing and purification protocols were adequate to eliminate it. The answer, according to plaintiffs’ experts, is that they were not.
Play 2: “There is no proven biological mechanism for talc causing ovarian cancer.” The defense will cite epidemiological studies with mixed results and argue that the scientific community has not established a universally accepted pathway by which talc exposure in the genital area causes ovarian cancer. The counter is twofold. First, multiple epidemiological studies have found an elevated risk of ovarian cancer associated with long-term genital talc use, and the International Agency for Research on Cancer has classified perineal use of talc-based body powder as “possibly carcinogenic to humans” (Group 2B). Second, the absence of a single universally accepted mechanism does not mean causation cannot be proven — it means the plaintiff’s experts must present reliable methodology and the defense’s experts must be cross-examined. In jurisdictions that apply the Daubert standard, the court acts as a gatekeeper for expert admissibility, and the battle is over whether the plaintiff’s methodology is reliable, not whether every scientist agrees.
Play 3: “The cancer was caused by something else — genetics, endometriosis, obesity, hormone therapy, or random chance.” This is where genetic-marker-negative status becomes the plaintiff’s strongest weapon. When BRCA testing and other hereditary markers come back negative, the defense’s preferred alternative explanation is eliminated. Combined with a documented decades-long exposure history and the absence of other significant risk factors, the specific-causation argument becomes substantially more difficult for the defense to defeat. The defense will still try — they will argue that ovarian cancer can be idiopathic, meaning it arises without an identifiable cause — but a woman who used the product daily for decades and has no genetic predisposition presents a compelling causation narrative.
Play 4: “The statute of limitations has expired.” The defense will argue that too much time has passed between the exposure and the lawsuit. The counter is the discovery rule — a legal doctrine adopted in many states that measures the statute of limitations not from the date of exposure but from the date the plaintiff discovered, or through reasonable diligence should have discovered, the injury and its causal connection to the product. For a woman who used talcum powder for decades and was diagnosed with ovarian cancer, the clock may not have started until the diagnosis — or until she learned that her cancer could be connected to talc exposure. The specific rule varies by state, which is why confirming the controlling deadline in your jurisdiction is something that must happen early.
Play 5: “We already told consumers — the label was adequate.” The company will argue that its product labeling met regulatory requirements. The counter is the 1960s memo — if the company’s own scientists told it that tremolite should be minimized and baby safety could no longer be guaranteed, and the company then marketed the product as pure and safe for babies without any warning about asbestos or cancer risk, the adequacy of the warning is a question for a jury, not a regulatory compliance defense.
Case Value: What a Talcum Powder Cancer Case Is Honestly Worth
We are going to give you honest ranges — not promises, not predictions, not marketing. Every case is different, and the value of any individual claim depends on the specific facts, the jurisdiction, the strength of the causation evidence, the severity of the injury, and whether punitive damages are available.
For individual US ovarian-cancer claims against Johnson & Johnson, the range we have seen in the litigation runs from approximately $3 million on the low end to $100 million or more on the high end, depending on venue, the strength of specific-causation evidence, and punitive-damages availability. Mesothelioma claims may command higher values because the causal link to asbestos is more directly established.
The article references a $1.5 billion verdict in Baltimore in a mesothelioma case involving lifetime use of J&J talc products. That is the extreme high end of the verdict spectrum — a single jury’s decision in a specific case. We must be clear: a verdict is not a final recovery. Verdicts can be reduced on appeal, and the procedural status of any specific verdict must be confirmed before it is treated as a settled result. What it does demonstrate is that juries, when confronted with the evidence of corporate knowledge and decades of concealment, have been willing to assign extraordinary value to the harm.
The factors that drive case value include:
- Injury severity — stage four cancer commands more than early-stage disease; a terminal diagnosis commands more than a treatable one
- Corporate-knowledge evidence — the 1960s memo and the decades of continued marketing without warning are the evidence that supports punitive damages
- Defendant resources — Johnson & Johnson is a deep-pocket defendant with the ability to pay substantial awards
- Specific causation strength — a claimant who tested negative for genetic markers and has a documented decades-long exposure history presents a stronger causation case
- Punitive damages — in US jurisdictions that permit them, the evidence of corporate knowledge and concealment supports a punitive-damages claim that can substantially exceed compensatory damages
- Survival and wrongful-death damages — where a claimant has succumbed, the specific damage split is governed by each state’s survival-statute and wrongful-death framework
Economic damages include past and future medical expenses — surgical intervention, chemotherapy, radiation, ongoing oncological monitoring, palliative care — along with lost wages and diminished earning capacity. Non-economic damages encompass physical pain, emotional distress, loss of quality of life, and the psychological trauma of a cancer diagnosis linked to a trusted household product. In US jurisdictions, punitive damages are a central damages component given the 1960s memo and the alleged decades-long concealment.
Past results depend on the facts of each case and do not guarantee future outcomes. The figures above are ranges drawn from the public litigation landscape, not a prediction of what your case will produce. The only way to know what your specific facts are worth is a confidential consultation with a trial attorney who can evaluate your exposure history, your medical records, and the law of your state.
The Statute of Limitations: Why the Clock May Start When You Were Diagnosed — Not When You Used the Powder
This is the question we hear most often from women who used talcum powder decades ago: Is it too late?
For toxic-exposure claims — diseases caused by a product used years or decades before the cancer appeared — many states apply what is called the discovery rule. Under this doctrine, the statute of limitations does not begin running on the date of exposure. It begins running when the plaintiff discovers, or through reasonable diligence should have discovered, the injury and its causal connection to the product.
For a woman who used Johnson & Johnson talcum powder from the 1970s through the 2000s and was diagnosed with ovarian cancer in 2024, the argument is that the clock did not start in the 1970s when she first used the product. It started when she was diagnosed — or when she first learned that her cancer could be connected to talc exposure. Under that theory, her filing deadline may be measured from the date of diagnosis, not the date of first use.
But this is not universal. Some states impose an outer deadline — a statute of repose — that can cut off a claim even before discovery. The discovery rule does not defeat a repose statute. The specific statute of limitations, the accrual trigger, and any repose period are governed by the law of the state where the claim would be filed. These vary across jurisdictions and are subject to legislative amendment and judicial interpretation.
We cannot tell you on a webpage whether your claim is timely. What we can tell you is this: the assumption that decades of powder use means the deadline has passed is often wrong, and the only way to know for certain is to have the specific deadline in your state confirmed by an attorney. The consultation is free, and confirming the deadline costs you nothing. Waiting and losing the right to file costs everything.
The First Steps: What to Do Now
If you or a loved one used Johnson & Johnson talcum powder for years and was diagnosed with ovarian cancer or mesothelioma, here is what should happen — in order.
First, preserve the product. If there is any remaining talcum powder — any bottle, any container, any vintage — do not throw it away. Store it in a sealed bag or container. It may be independently testable for asbestos contamination, and that testing can provide direct physical evidence linking the specific product you used to the contaminant that caused the disease. Talc-based baby powder has been phased out of US markets and discontinued in the UK, making remaining containers increasingly rare and increasingly valuable as evidence.
Second, collect the medical records. Pathology reports, genetic testing results (especially BRCA panel results), treatment history, imaging, and surgical reports. These establish the diagnosis, the staging, the absence of hereditary factors, and the medical damages. Request them from every treating facility — hospitals, oncology clinics, imaging centers. Treating facilities have retention policies, and records can become harder to obtain over time.
Third, document the exposure history. Write down everything you can remember about your talcum powder use — when you started, how often you used it, where you applied it, what brand, what size containers, where you purchased it, and when you stopped. Ask family members who may remember. Look for old purchase receipts, subscription records, or photographs that show the product in your home. This history is the foundation of the specific-causation argument.
Fourth, do not sign anything from the company or its representatives. If you receive any communication from Johnson & Johnson, Kenvue, their insurers, or anyone claiming to represent them — do not sign it, do not return it, do not respond to it without speaking to a lawyer first. A document that looks like a routine survey or a harmless questionnaire can contain a release that extinguishes your rights.
Fifth, call a trial attorney. The consultation is free. The preservation letter that freezes corporate evidence goes out the day you retain counsel. The medical records are collected. The exposure history is documented. The product container, if it exists, is secured and tested. The statute of limitations is confirmed. These are not things to do eventually. They are things to do now, because the evidence is on a clock and the deadline is real.
Frequently Asked Questions
Can I sue Johnson & Johnson if I used talcum powder and got ovarian cancer?
You may have a claim if you used Johnson & Johnson talcum powder regularly for years — particularly for personal hygiene — and were subsequently diagnosed with ovarian cancer, especially if you tested negative for genetic cancer markers like BRCA. The strength of your case depends on your exposure history, your medical records, the alternative-causation analysis, and the law of your state. A confidential consultation with a trial attorney can evaluate whether your specific facts support a claim.
I used baby powder decades ago. Is it too late to file a lawsuit?
Not necessarily. Many states apply a discovery rule for toxic-exposure claims, meaning the statute of limitations may start when you were diagnosed or when you learned your cancer could be connected to talc — not when you first used the product. However, some states impose an outer deadline called a statute of repose that can cut off a claim regardless of discovery. The only way to know whether your claim is timely is to have the specific deadline in your state confirmed by an attorney. The consultation is free.
What if I tested negative for BRCA and other genetic cancer markers?
Testing negative for genetic markers is one of the strongest pieces of evidence a talc plaintiff can have. When hereditary factors are ruled out, the most common alternative explanation for ovarian cancer is eliminated, which sharpens the argument that an external exposure — like asbestos-contaminated talc — caused the disease. This does not guarantee causation, but it substantially strengthens the specific-causation narrative.
Does Johnson & Johnson talcum powder really contain asbestos?
Talc and asbestos form in the same geological deposits, and independent laboratory testing of talcum powder samples has found asbestos fibers, including tremolite. Johnson & Johnson has consistently maintained that its products do not contain asbestos. The 1960s internal memo referenced in the Scottish litigation — in which the company’s own scientific advisors recommended minimizing tremolite and acknowledged that talc safety for babies could no longer be guaranteed — is evidence that the company was aware of the contamination risk decades ago.
What is the difference between the ovarian cancer claims and the mesothelioma claims?
Mesothelioma is a cancer specifically associated with asbestos exposure — the disease itself is near-conclusive proof of asbestos exposure, which makes the causal link to asbestos-contaminated talc more direct. Ovarian cancer has multiple potential causes, including genetic factors, endometriosis, and hormonal factors, which makes the causation argument more contested. Both types of claims are being pursued in the talc litigation, but mesothelioma claims generally command higher values due to the stronger causal link and the disease’s characteristic lethality.
What is Kenvue and why is it being sued instead of Johnson & Johnson?
Kenvue is the consumer-health business that Johnson & Johnson separated as an independent company in August 2023. Johnson & Johnson has stated that Kenvue indemnified J&J for talc-related litigation outside the United States and Canada, which is why Kenvue is named in the Scottish action. In US cases, both J&J and Kenvue may face liability depending on the corporate-separation structure and indemnification agreements. Identifying the correct defendant — or defendants — is a critical early step that requires examining the corporate structure and the specific facts of when and where the exposure occurred.
What should I do if I still have a bottle of Johnson & Johnson baby powder?
Do not discard it. Store it in a sealed container. Talc-based baby powder has been discontinued in the UK and phased out in US markets, making remaining containers increasingly rare as physical evidence. The powder inside may be independently testable for asbestos contamination using transmission electron microscopy, and that testing can provide direct physical evidence linking the specific product you used to the contaminant that may have caused your disease.
How much is a talcum powder cancer case worth?
Individual US ovarian-cancer claims against Johnson & Johnson have ranged from approximately $3 million on the low end to $100 million or more on the high end, depending on venue, causation strength, injury severity, and punitive-damages availability. Mesothelioma claims may command higher values. A $1.5 billion verdict in a Baltimore mesothelioma case represents the extreme high end of the verdict spectrum. Past results depend on the facts of each case and do not guarantee future outcomes. The only way to know what your specific case is worth is a confidential evaluation with a trial attorney.
What does it cost to hire a lawyer for a talcum powder cancer case?
Our firm works on contingency. That means we do not charge an hourly fee. We advance the costs of the case, and we are paid only if we win — a percentage of the recovery. If there is no recovery, there is no fee. The initial consultation is free, and it is confidential. You can call 1-888-ATTY-911 at any hour, and you will speak to a live person, not an answering service.
Will I have to go to court?
Many mass-tort cases are resolved through settlement before trial, but every case must be prepared as if it will be tried. The strength of your evidence — the exposure history, the medical records, the product testing, the corporate documents — is what drives settlement value, and that strength is built by a trial team that prepares from day one for the possibility of a jury. Whether your specific case settles or goes to trial depends on the facts, the defendant’s posture, and the jurisdiction.
The Firm: Who We Are and What We Do
Ralph P. Manginello is our Managing Partner. He has been licensed to practice law in Texas since November 6, 1998 — 27+ years in courtrooms, including federal court in the U.S. District Court, Southern District of Texas. He was a journalist before he was a lawyer, which means he was trained to find the story the evidence tells — and to tell it to a jury in language they cannot forget. He is a member of the Texas Trial Lawyers Association, the Houston Bar Association, and the National Association of Criminal Defense Lawyers, among others. He leads our firm’s trial work, and his background and credentials are available here.
Lupe Peña is our Associate Attorney. He spent years inside a national insurance-defense firm — the rooms where claims like yours are priced, where adjusters and their software decide how to deny, delay, and devalue people exactly like you. He sat across the table from the insurance industry. Now he sits on your side of it. He is fluent in Spanish and conducts full client consultations in Spanish without an interpreter. His background and credentials are available here.
We handle cases on contingency. The fee is 33.33% before trial and 40% if the case goes to trial. We advance the costs. We don’t get paid unless we win your case. The initial consultation is free and confidential. You can reach us at 1-888-ATTY-911, 24 hours a day, seven days a week. You will speak to a live person on our staff — not an answering service, not a call center.
If you or someone you love used Johnson & Johnson talcum powder for years and was diagnosed with ovarian cancer or mesothelioma, the evidence that could prove the connection is on a clock. The product containers are disappearing. The medical records are aging. The corporate documents that show what the company knew and when it knew it can be lost if no one demands they be preserved. The statute of limitations in your state is real, and it may be running.
We are not the counsel of record in the Scottish case or in any specific talc litigation we are not named in. What we are is a trial firm with 27+ years of experience in toxic tort and product-liability cases, wrongful-death claims, and the kind of corporate-accountability fights that a case like this demands. If you want to know whether your facts support a claim, call us. If we are not the right fit for your case, we will tell you. If you want to understand how contingency fees work and what your case might be worth, we will explain it in plain language. If you want to know what you should never say to an insurance adjuster, we will tell you that too.
Hablamos Español. Lupe conducts full consultations in Spanish without an interpreter. If your family is more comfortable in Spanish, call us at 1-888-ATTY-911 and ask for Lupe.
Past results depend on the facts of each case and do not guarantee future outcomes. This page is legal information, not legal advice. Nothing here creates an attorney-client relationship. For that, you have to call — and when you do, the conversation is free, confidential, and the first step in finding out whether the product you trusted for decades is the reason you are fighting for your life now.